Neoprospecta Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
50
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$8.28M
Neoprospecta General Information
Description
Developer of a biotechnology platform designed to help researchers deal with microbiological analysis, management, and control. The company's platform offers biocomputational analysis and quantitative PCR techniques which have created a line of rapid tests for the detection of microorganisms and antibiotic-resistance genes, enabling medical researchers to identify microorganisms using DNA sequencing technologies.
Contact Information
Website
www.neoprospecta.com(Operating Subsidiary)
Corporate Office
- Avenida Luiz Boiteux Piazza
- Number 1302, Sapiens Parque, Canasvieiras
- Florianopolis, 88054
- Brazil
Corporate Office
- Avenida Luiz Boiteux Piazza
- Number 1302, Sapiens Parque, Canasvieiras
- Florianopolis, 88054
- Brazil
Neoprospecta Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 29-Jan-2025 | $8.28M | Completed | Generating Revenue | ||
| 6. Later Stage VC | 14-May-2021 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 01-Feb-2024 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 01-Jun-2016 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 08-Aug-2014 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 15-Feb-2013 | $249K | $249K | Completed | Generating Revenue | |
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Neoprospecta Patents
Neoprospecta Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20160273031-A1 | Method, kit and premix for quantitative and discriminative determination of nucleic acids, qdpcr; in vitro method for the quantitative and discriminative diagnosis of biological entities | Inactive | 18-Nov-2013 | ||
| WO-2015070309-A1 | Method, kit and premix for quantitative and discriminative determination of nucleic acids, qdpcr; in vitro method for the quantitative and discriminative diagnosis of biological entities | Inactive | 18-Nov-2013 |
Neoprospecta Signals
Neoprospecta Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Associação Catarinense de Tecnologia | Accelerator/Incubator | |||
| CRP Companhia de Participacoes | Venture Capital | Minority | ||
| CVentures | Corporate Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| IDEE (Other Commercial Products) | Venture Capital | Minority |
Neoprospecta FAQs
-
When was Neoprospecta founded?
Neoprospecta was founded in 2011.
-
Where is Neoprospecta headquartered?
Neoprospecta is headquartered in Florianopolis, Brazil.
-
What is the size of Neoprospecta?
Neoprospecta has 50 total employees.
-
What industry is Neoprospecta in?
Neoprospecta’s primary industry is Biotechnology.
-
Is Neoprospecta a private or public company?
Neoprospecta is a Private company.
-
What is the current valuation of Neoprospecta?
The current valuation of Neoprospecta is .
-
What is Neoprospecta’s current revenue?
The current revenue for Neoprospecta is .
-
How much funding has Neoprospecta raised over time?
Neoprospecta has raised $2.49M.
-
Who are Neoprospecta’s investors?
Associação Catarinense de Tecnologia, CRP Companhia de Participacoes, CVentures, , and IDEE (Other Commercial Products) are 5 of 7 investors who have invested in Neoprospecta.
-
When was Neoprospecta acquired?
Neoprospecta was acquired on 29-Jan-2025.
-
Who acquired Neoprospecta?
Neoprospecta was acquired by BioMérieux.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process